Introduction
This article describes recent advances in our understanding of the pathogenesis and treatment of the neurological disorders associated with human immunodeficiency virus-i (HIV-1) infection. Readers in search of a general overview of 'AIDS neurology' are referred to two recent reviews.",2
Neurological disease in primary HIV-1 infection
Primary infection with HIV-1 may pass unnoticed or be passed off as an unremarkable viral illness. A glandular fever-like illness occurs in 30-60% of patients.3'4 Neurological symptoms have included headache in 30%, with nausea and vomiting in 20%, an encephalopathy in 8% and neuropathies in a further 8%, often including a peripheral seventh nerve palsy. Rarer manifestations have included an aseptic meningitis,5 encephalitis,6 a myelopathy7 and acute rhabdomyolysis.8 The Guillaine-Barre syndrome is no longer regarded as being associated with HIV-1 more often than any other acute viral infection. HIV-1 can be isolated in high titre from blood and cerebrospinal fluid (CSF) of these patients9 and this should be borne in mind when performing lumbar punctures.
The route ofentry ofthe virus into the CSF is not certain. The virus is tropic for cells bearing the CD4 receptor (although other receptors include galactocerebroside'°). Current dogma, extrapolating from knowledge of retroviral behaviour in other hosts, is that the virus gains entry to the central nervous system (CNS) early in the course ofdisease by infecting trafficking macrophages and/or CD4-positive lymphocytes." "2 An alternative, and not mutually exclusive hypothesis is that virus may bind to endothelial cells in the cerebral circulation expressing CD4 or Fc receptors'3 and gain entry to the CNS. It is not yet clear whether neurological symptoms at this stage predispose to later CNS disease. There Correspondence: R.K.H. Petty, M.D., M.R.C.P.(UK). Accepted: 24 January 1994 is some evidence from a retrospective study that symptomatic acute infection is associated with a 68% risk of developing AIDS in the subsequent 5 years, compared to 20% in asymptomatic seroconverters,'4 although other factors such as mode of transmission and reporting characteristics may have influenced these data. Late clinical presentation with neurological features is associated with a worse prognosis."5
Neurological disease associated with established HIV-J infection
The manifestations of established HIV-1 infection have traditionally, and for largely epidemiological purposes, been divided into those occurring during the 'asymptomatic' period and those associated with immunosuppression. The neurological features have been divided into infections, tumours, primary HIV-l-mediated diseases and vascular disease, although these divisions are of limited practical clinical value. Certain disorders are associated with particular levels ofimmunosuppression and these will therefore be discussed by presenting features, and the stages at which individual complications develop will be indicated.
Meningitis
A low-grade lymphocytic meningitis has been described in postmortems performed on asymptomatic infected drug users who have died early in the course of their disease from factors not related to HIV-1 infection.'6"7 The CSF is abnormal with 50% or more of all patients showing a raised protein, oligoclonal bands and a lymphocytic pleocytosis. HIV-1 is present in 20%.18-20 Patients may experience recurrent episodes of an aseptic meningitis but the pathological changes would appear to be entirely asymptomatic in the majority. There is no evidence as yet that these changes predict the later development of any of the neurological complications of HIV infection.
Meningitis may also be due to organisms other than HIV-l (Table I ). There are no specific clinical Diffuse encephalopathies The AIDS dementia complex (ADC) or HIV-associated cognitivemotor complex (among other aliases39) is perhaps the most feared of the neurological diseases in AIDS. It is a diagnosis ofexclusion during life with a very broad differential diagnosis (Table II) . Early estimates were of an incidence up to 60% but more recent figures are lower at around 10%. 4 The clinical presentation is as a subacutely evolving 'subcortical' dementia; characterized by slowness of thought, loss of initiative and poor memory often in association with neurological signs such as dystonias, ataxia and tetraparesis leading to death in 3-4 months from onset.41 Focal cortical symptoms such as aphasia, agnosias and apraxias are uncommon. Staging systems and diagnostic criteria have been proposed,42'43 but these are essentially descriptive and thorough investigation of all patients is essential. The aetiology of this dementing illness is not known. The neuropathological changes are listed in Table III Severe depressive illness It is thought HIV-l infects only the microglia, lymphocytes and possibly endothelial cells in the CNS and there is no convincing in vivo evidence that HIV-1 infects neurones, astrocytes or oligodendrocytes (although such infection has been produced in experimental models.5657) A current hypothesis states that the neuronal death, the leucodystrophy and the dementia are secondary to the replication of HIV-1 in macrophages, and the products of the activation of macrophages and lymphocytes through two mechanisms: (1) the generation of virally encoded glycoproteins and regulatory proteins, such as gp120 and tat, thought to be directly toxic to both neurones and oligodendrocytes; and (2) the production of macrophageand lymphocyte-derived factors, such as tumour necrosis factor a, quinolinic acid, excitatory amino acids and nitric oxide which are also neuronotoxic, damage myelin and may play a part in the breakdown of the blood-brain barrier, another possible pathogenetic mechanism58-6' (see Table IV ). It is important when considering mechanisms to recall that there is no correlation between these neuropathological and neurochemical changes, and the severity of the clinical dementia.55'62'63 and functional magnetic resonance (MR) imaging87 have also been described, but it has not proven possible as yet to correlate these changes with intellectual state or prognosis. Similar reservations apply to reports of atrophy on CT88 and MR scans.89"9 There is thus emerging evidence of subclinical cerebral pathology in patients infected with HIV-1, but the relevance ofthis to the ADC or clinical practice is not yet clear.
Cytomegalovirus (CMV) and Varicella zoster virus may produce a subacute encephalitis, and CMV may exacerbate HIV-1-related pathology by activating gene expression.92 CMV infections are associated with advanced disease and patients often have associated retinopathies, hypoadrenalism or evidence of neuropathy. The treatment of CMV infection is discussed below in the context of peripheral nerve disease.
There is also a wide range of possible causes of focal neurological dysfunction of which the most frequent are discussed below (and see Table V) .
Toxoplasmosis develops in 6-12% of HIV-1-infected patients, usually as the CD4 cell count drops below 150/mm3. The presentation is of a subacutely evolving mass lesion with headache (c. The incidence of cerebrovascular disease in HIV infection depends on the population studied. Pathological studies have reported frequencies of infarction and haematoma up to 20%, while clinical reports are of < 1-10% incidence of 'stroke'."7 The majority ofclinical events are due to embolization in intravenous drug abusers and other patients with infective or non-infective endocarditis, as well as haemorrhage in haemophiliacs. There are recent reports of 'transient ischaemic attack' (TIA)-like episodes in patients."8 These attacks are often longer lasting than true TIAs, occur up to 20 times per day, do not seem to presage ischaemic stroke, and may respond to zidovudine and may therefore be on a different basis. There are pathological reports of vasculopathies60"6"9 as well as abnormalities in blood flow as assessed by single photon emission computerized tomography (SPECT)'20"2' and it is conceivable these are in some way related to these episodes. Stroke syndromes may also follow trigeminal zoster and be associated with the chronic meningitides and syphilis.
Myelopathies
There are three myelopathies associated with HIV-1, but their diagnosis is one of the exclusion and myelography or spinal MR imaging are essential to exclude compressive lesions, such as lymphomatous deposits or chronic meningitis (Table VI) Chronic inflammatory demyelinating neuropathies, though rare, occur with increased frequency in seropositive patients, most often during the asymptomatic period. The clinical presentation, nerve conduction studies and nerve biopsy are similar to those in the HIV-negative population, and the only hint of HIV seropositivity may be a CSF lymphocytosis, atypical for inflammatory demyelinating polyneuropathy.'36 Cytomegalovirus has been implicated in a variety of neuropathies, usually in association with advanced disease. It is associated with a painful lumbosacral polyradiculopathy presenting with foot parasthesiae, weakness and, over a few days, paraparesis, or paraplegia and urinary retention. The upper limbs are usually spared unless the infection is untreated. CSF shows a marked polymorphocytosis up to 1,000/mm3, with a raised protein and slightly lowered sugar. Cytomegalovirus can be isolated from CSF and electromyography studies ofaffected muscles show evidence of acute denervation.'37l39 Early treatment with ganciclovir (5 mg/kg i.v. twice daily for 10-14 days) may preserve lower limb function and maintenance therapy is essential to avoid relapse. Both CMV and Varicella zoster virus have been implicated in a mononeuritis multiplex and diffuse polyradiculopathies.'38140 These cases may present as a confluent neuropathy, so mimicking the axonal neuropathy of HIV, and full assessment with nerve conduction studies is essential to make the diagnosis. There are anecdotal reports of a response to zidovudine but, more often, therapy is directed toward symptomatic measures, such as carbamazepine, phenytoin, tricyclic drugs and transcutaneous nerve stimulation. Entrapment neuropathies can become a problem as patients lose weight. The most commonly involved is the lateral cutaneous nerve of thigh, and its involvement may herald a more diffuse neuropathy.129
There are recent reports of a motor axonopathy in HIV-l infection, which may mimic motor neurone disease, although these must be extremely rare 141, 142 Finally, it is important to recognize that many of the drugs used in the treatment of HIV-1-infected patients may cause neuropathies and, of the retroviral agents, both dideoxycytidine and dideoxyinosine may cause a painful sensory neuropathy. 143,"4 5. Muscle disease An inflammatory necrotizing myopathy occurs, most frequently during the asymptomatic period, clinically indistinguishable from polymyositis. 145",46 Patients present with a subacute painful proximal myopathy, associated with elevated levels of serum creatine kinase and a myopathic electromyogram. Muscle biopsy, essential to distinguish this process from the myopathies associated with advanced HIV disease and zidovudine treatment described below, shows necrosis with a macrophage and CD8 + lymphocytic infiltrate.'47 Perifasicular atrophy is infrequently seen, nemaline rods may be prominent, and the inflammatory infiltrate may be minor. These features have led some to question whether this is true polymyositis or a novel necgroup.bmj.com on June 21, 2017 -Published by http://pmj.bmj.com/ Downloaded from rotizing myopathy occurring in the context of HIV infection and pre-existing inflammatory change.'48 The pathogenesis is unclear and HIV is only present within infiltrating macrophages. There are no trials to support any mode of therapy but most workers recommend prednisolone in the doses used for conventional polymyositis with anecdotal reports of response. There is evidence for a HIVspecific myopathy distinct from the inflammatory myopathy referred to above and the zidovudine myopathy referred to later. This is usually associated with advanced disease. Patients develop weakness, myalgia elevated serum creatine kinase levels and muscle biopsy shows myofibre degeneration, cytoplasmic bodies, nemaline rods and myofibrillar loss.'49 The cause is unclear and there is no proven treatment.
There is considerable debate concerning whether or not zidovudine may give rise to a mitochondrial myopathy.'48"50 It has an inhibiting action on the mitochondrial y-DNA polymerase and has been shown in animal models to produce morphological and biochemical changes consistent with a mitochondrial myopathy. ' 
